Alpha Teknova, Inc. (Teknova)

Company overview

Alpha Teknova, Inc. (Teknova) is a life sciences company that manufactures critical reagents used in the discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. The company serves more than 3,000 customers, including pharmaceutical and biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostics franchises, and academic and government research institutions.

Teknova focuses on proprietary manufacturing know-how, adaptable processes, and fast turnaround to deliver custom, made-to-order products at scale across all stages of product development, including commercialization. Headquarters and manufacturing operations are in Hollister, California, on a campus of about 190,000 square feet, including approximately 12,500 square feet of clean room space.

Products and customer engagement

Primary product categories:

• Lab Essentials
• Clinical Solutions

Product types (across both categories, with one exception):

• Pre-poured media plates for cell growth and cloning (Lab Essentials only)
• Liquid microbial culture media and supplements for cellular expansion
• Molecular biology reagents for sample manipulation, resuspension, purification, and related uses

Customer engagement model:

• Customers start with off-the-shelf (catalog) formulations during discovery.
• As needs evolve for higher performance, larger volumes, or GMP requirements, customers transition to higher-value custom or GMP-grade products.
• Teknova offers rapid production and customization of inputs, formulations, packaging, labeling, and quality controls to meet customer specifications.

Security of supply and regulatory stance:

• Teknova maintains ISO 13485:2016 certification to align with regulatory expectations in regulated contexts.
• Products marketed as Clinical Solutions or GMP-grade are designed for use in diagnostic kits, protein therapies, gene therapies, mRNA vaccines, and related manufacturing processes.

Revenue mix and market context (2025)

• Revenue by product category:
  • Lab Essentials: 76.6% of total revenue (approximately 75% catalog, 25% custom)
  • Clinical Solutions: 18.9% of total revenue (approximately 90% custom, 10% catalog)
• RUO versus GMP-grade:
  • Lab Essentials products are largely research-use-only (RUO) catalog items for early-stage development.
  • Clinical Solutions products are GMP-grade for later-stage development and production.
• Cell and gene therapy customer dynamics:
  • Teknova serves about 95 active cell and gene therapy customers purchasing more than $5,000 annually.
  • Of these customers:
    • 49% purchased $5,000+ per year of catalog products only
    • 20% purchased catalog plus custom products
    • 31% purchased catalog, custom, and GMP-grade products
• Geographic footprint:
  • In 2025, approximately 94.4% of total revenue came from customers in the United States.
• Delivery speed and scale:
  • In 2025, roughly 79% of custom RUO products shipped within three weeks.
  • The company has invested in automation and facilities to scale production and reduce turnaround times.

Customers, employees, and leadership

• Customers: more than 3,000
• Employees: 158 full-time employees as of December 31, 2025
  • 88 in operations
  • 45 in administrative functions
  • 15 in sales and marketing
  • 10 in engineering and R&D
• Leadership and capabilities: experienced management across life sciences, diagnostics, and biopharmaceutical markets, supported by a workforce focused on customer support, quality systems, and manufacturing.

Growth strategy and operations

Strategic aims:

• Increase integration of Teknova products into customers’ workflows
• Improve customer service through operational excellence, automation, and infrastructure investments to boost capacity and reduce turnaround times
• Pursue selective geographic expansion and partnerships, including Europe-focused distribution, localized manufacturing, and targeted acquisitions or collaborations

Competitive positioning:

• Teknova highlights its ability to deliver highly customized formulations with short turnaround times, supported by decades of process optimization and a product database of formulations from thousands of previously produced products.

Intellectual property approach:

• Teknova does not own issued patents covering its products and relies on trade secrets, confidential information, and ISO-aligned quality controls to protect its position.

Regulatory posture:

• Clinical Solutions and GMP-grade products meet higher quality and regulatory expectations; RUO labeling is used for research-use-only components consistent with FDA RUO/IUO guidance considerations.

Financial snapshot highlights (from 2025 annual disclosures)

• Net income: net losses of $17.3 million in 2025 and $26.7 million in 2024.
• Ownership and governance:
  • Telegraph Hill Partners, via affiliates THP IV and THP V, controls approximately 70.4% of the voting power of Teknova’s outstanding common stock.
  • Teknova is a “controlled company” under Nasdaq rules.
  • Publicly listed on Nasdaq under the symbol TKNO; IPO completed in 2021.
• Capital structure notes:
  • Teknova has a Second Amended and Restated Credit Agreement with covenants that restrict certain actions and require maintenance of financial metrics; the indebtedness is secured by substantially all assets.
• Dividends:
  • The company does not plan to pay regular cash dividends, and debt covenants restrict dividend payments unless consent is obtained.

Key takeaways

• Teknova is a specialized contract manufacturer and supplier of customized chemical formulations and molecular biology reagents for life sciences, focused on rapid delivery and customization across discovery to commercialization.
• The two main product categories (Lab Essentials and Clinical Solutions) cover catalog and custom RUO offerings and GMP-grade solutions across pre-poured plates, liquid media, and molecular biology reagents.
• The business is U.S.-centric but pursuing selective international expansion, with a large installed customer base and a material portion of revenue from custom and GMP-grade products.
• Financials show ongoing net losses in 2025 and 2024, with revenue weighted toward Lab Essentials.
• Teknova is controlled by a single major shareholder (Telegraph Hill Partners) and operates under debt covenants, with ISO 13485:2016 certification and a strategy centered on deep customer relationships and fast, customized production.